Psoriatic arthritis Trials in Palm Harbor, United States
Conditions / Psoriatic arthritis / Palm Harbor, United States
Clinical trials for Psoriatic arthritis investigate a range of treatment strategies and patient populations.
13 total trials for this combination
Showing top 10 of 13 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03895203 | A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis | COMPLETED | PHASE3 |
| NCT01882439 | Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors | COMPLETED | PHASE3 |
| NCT01989468 | 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis | COMPLETED | PHASE3 |
| NCT03104400 | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | COMPLETED | PHASE3 |
| NCT03104374 | A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug | COMPLETED | PHASE3 |
| NCT01877668 | Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study | COMPLETED | PHASE3 |
| NCT03896581 | A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis | COMPLETED | PHASE3 |
| NCT04009499 | A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT02538341 | Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial) | COMPLETED | PHASE2 |
| NCT02798211 | Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo | COMPLETED | PHASE4 |